These results reinforce the existing large body of evidence for pertuzumab in HER2-positive breast cancer, and support the favorable benefit–risk profile of the pertuzumab-based regimen in Chinese patients in the first-line metastatic setting. This evidence concerns the gene ERBB2 and breast carcinoma.